Interpace Diagnostics Group Stock News

The

Interpace Diagnostics Group (NASDAQ:IDXG) was downgraded by stock analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued on Friday, ValuEngine reports. A

In a report released today, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Moleculin Biotech (MBRX – Research Report),

In a report released today, Yi Chen from H.C. Wainwright initiated coverage with a Buy rating on Applied DNA Sciences

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.36%

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA

Interpace Diagnostics Group (NASDAQ:IDXG) announced its quarterly earnings results on Thursday. The business services provider reported ($2.32) earnings per share for the quarter, missing analysts’

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Interpace Diagnostics Group (IDXG – Research Report) yesterday and set a

Q1 2020 Interpace Biosciences Inc Earnings Call

First Quarter Net Revenue Improved Over 53% to $9.2 Million Launching COVID-19 Serology Testing Continues to Integrate Service Offerings and Streamline Costs Conference Call.

Interpace Biosciences, Inc. (NASDAQ:IDXG) Q1 2020 Earnings Conference Call June 25, 2020 04:30 PM ET Company Participants Jack Stover - President and CEO Fred K

Maxim Group analyst Jason McCarthy assigned a Buy rating to Titan Pharmaceuticals (TTNP – Research Report) today and set a

In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Soligenix (SNGX – Research Report),

Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial results on Thursday, June 25, 2020 at 4:30 p.m. ET. Interpace will host a conference call and webcas